8-K: Cabaletta Bio Announces Positive Clinical Data for CABA-201 in Autoimmune Diseases

Cabaletta Bio reports promising clinical data for CABA-201, showing potential for drug-free responses in autoimmune patients across multiple trials.

Summary

• Cabaletta Bio presented new clinical data on CABA-201 at the American College of Rheumatology (ACR) Convergence 2024, demonstrating potential for drug-free clinical responses.
• The data is based on eight patients dosed across Phase 1/2 RESET-Myositis, RESET-SLE, and RESET-SSc clinical trials.
• CABA-201 showed a favorable safety profile, with no evidence of cytokine release syndrome (CRS) in five patients and low-grade CRS in three, all of whom recovered without tocilizumab.
• No immune effector cell-associated neurotoxicity syndrome (ICANS) was observed, except for one previously reported case in a lupus nephritis patient who had pre-existing inflammatory issues.
• The treatment induced consistent and complete B cell depletion by day 22, with early nave B cell repopulation starting as early as 8 weeks.
• Clinical responses were observed in all four SLE patients, with one completing a prednisone taper.
• The first patient in the severe skin cohort of the RESET-SSc trial showed early clinical improvements.
• All eight patients discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data with a favorable safety profile and promising efficacy results. The company is also expanding its clinical network and moving towards regulatory discussions, which are all positive indicators. However, the one ICANS event and the pulmonary embolism, while not directly related to the therapy, temper the overall sentiment slightly.

Positives

• CABA-201 has shown a favorable risk-benefit profile with manageable side effects.
• The treatment led to consistent and complete B cell depletion, which is a key goal for autoimmune disease therapy.
• Early B cell repopulation with a nave phenotype suggests a potential reset of the immune system.
• Patients showed compelling clinical responses, including improvements in muscle strength, disease activity scores, and proteinuria.
• All patients were able to discontinue immunosuppressants, indicating the potential for drug-free remission.
• The company has a growing clinical network with 40 actively recruiting U.S. sites and plans to expand to Europe in 2025.

Negatives

• One patient experienced Grade 4 ICANS, although this was linked to pre-existing inflammatory events and a possible occult infection.
• One patient experienced a pulmonary embolism, which was considered an unrelated serious adverse event but consistent with known risks of the preconditioning regimen.
• Three patients experienced low-grade CRS, although these were managed with standard care and did not require tocilizumab.

Risks

• The risk that signs of biologic activity or persistence may not inform long-term results.
• The risk that the results observed with the similarly-designed construct employed in academic publications are not indicative of the results we seek to achieve with CABA-201.
• Risks related to clinical trial site activation, delays in enrollment generally or enrollment rates that are lower than expected.
• Delays related to assessment of clinical trial results.
• Risks related to unexpected safety or efficacy data observed during clinical studies.
• Risks related to volatile market and economic conditions and public health crises.

Future Outlook

Cabaletta anticipates meeting with the FDA in 2025 to discuss potential registrational trial designs for CABA-201 and plans to expand clinical trials into Europe in 2025. The company expects to have initial clinical data in generalized myasthenia gravis (gMG) in the first half of 2025 and is also enrolling a pemphigus vulgaris (PV) trial without preconditioning. They are also working towards securing efficient and scalable commercial manufacturing.

Management Comments

• David J. Chang, M.D., Chief Medical Officer of Cabaletta, stated that CABA-201 displayed a consistent PK and PD profile, except for the patient with a second, later peak expansion.
• Management believes their efficient clinical trial design, growing footprint of 40 actively recruiting U.S. clinical sites, and anticipated expansion into Europe in 2025 provide a differentiated opportunity to accelerate development of CABA-201.

Industry Context

The announcement highlights the growing interest in CAR T-cell therapy for autoimmune diseases, moving beyond its established use in oncology. Cabaletta's approach of targeting CD19-positive B cells aligns with the understanding of B cell involvement in various autoimmune conditions. The company is leveraging the experience gained from oncology CAR T-cell therapies to develop treatments for autoimmune diseases.

Comparison to Industry Standards

• The use of a 4-1BB costimulatory domain in CABA-201 is consistent with some academic studies and other CAR T-cell therapies, such as tisagenlecleucel, which uses a CD8 transmembrane domain.
• The preconditioning regimen of fludarabine and cyclophosphamide is similar to that used in academic studies of CD19 CAR T-cell therapy for autoimmune diseases.
• The observed B cell depletion and repopulation kinetics are comparable to those seen in other CAR T-cell studies, both in oncology and autoimmune settings.
• The clinical responses observed in the myositis, SLE, and SSc patients are encouraging and suggest a potential for drug-free remission, which is a significant advancement over current chronic immunosuppressive therapies.
• The safety profile of CABA-201, with low rates of severe CRS and ICANS, is favorable compared to some oncology CAR T-cell therapies, although the one ICANS event highlights the need for careful patient selection and monitoring.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical data and the potential for regulatory approval.
• Patients with autoimmune diseases may see CABA-201 as a potential new treatment option with the possibility of drug-free remission.
• Employees of Cabaletta Bio may be motivated by the positive results and the company's progress.
• The medical community may be interested in the data and the potential of CAR T-cell therapy for autoimmune diseases.

Next Steps

• The company plans to meet with the FDA in 2025 to discuss potential registrational trial designs for CABA-201.
• Cabaletta intends to expand its clinical development program into Europe in 2025.
• The company will continue to enroll patients in the ongoing RESET clinical trials.
• Initial clinical data in generalized myasthenia gravis (gMG) is expected in the first half of 2025.
• The company is enrolling a pemphigus vulgaris (PV) trial of CABA-201 without preconditioning.

Key Dates

Keywords

CABA-201, CAR T-cell therapy, autoimmune disease, myositis, systemic lupus erythematosus, systemic sclerosis, B cell depletion, clinical trial, immunotherapy, RESET program